Malaria Global Clinical Trials Review 2025: G7 & E7, Phase, Trial Status, End Points Status And Sponsor Type Coverage

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Malaria - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
The report provides an overview of Malaria Clinical trials scenario. This report provides top line data relating to the clinical trials on Malaria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database.

Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

• Report Guidance
• The analyst Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Malaria to Infectious Disease Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Malaria to Infectious Disease Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Malaria Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Malaria
• Mar 11, 2025: Modus Therapeutics Announces Completion of Patient Enrollment in the SEVUSMART Phase I Study for Severe Malaria
• Feb 05, 2025: US Patent Granted Titled: Bifunctional Compositions for the Treatment of Cancer
• Jan 28, 2025: 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
• Jan 08, 2025: 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
• Clinical Trial Profile Snapshots
• Appendix

A selection of companies mentioned in this report includes, but is not limited to:

• GSK plc
• Sanaria Inc
• Novartis AG
• Nucleus Network Ltd
• Sanofi
• Shin Poong Pharm Co Ltd
• Pfizer Inc
• Sun Pharmaceutical Industries Ltd
• Shanghai Fosun Pharmaceutical (Group) Co Ltd
• IPCA Laboratories Ltd

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08052025004107003653ID1109524723